Topic
Psychotropic drug
About: Psychotropic drug is a research topic. Over the lifetime, 2309 publications have been published within this topic receiving 54070 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In comparing the blocking action of different psychotropic drugs on the mescaline-induced state, chlorpromazine and triflupromazine were found to be the most active, prochlorperazine and thiopropazate moderately so, while diethazine accentuated the mesaline response.
Abstract: In comparing the blocking action of different psychotropic drugs on the mescaline-induced state, chlorpromazine and triflupromazine were found to be the most active, prochlorperazine and thiopropazate moderately so, while diethazine accentuated the mescaline response. Promazine and promethazine were ineffective, a finding concurring with that in clinical practice. The intramuscular injection of these drugs after mescaline did not influence the continuous fall of amino acids and eosinophils [1].
4 citations
••
TL;DR: Despite improvements there is still a need for skill development in psychiatry.
Abstract: Despite improvements there is still a need for skill development in psychiatry
4 citations
•
01 Jan 2009
TL;DR: Evaluated literature data on suicidality risk and newer ATDs, investigate psychotropic drug prescribing trends, focusing on ATD use in general practice before and after the regulatory changes, and investigate treatment cessation for depression.
Abstract: Until recently, the use of antidepressant (ATD) drugs by young people for the treatment of psychiatric and behavioural disorders had increased in Europe and the United States. However in 2003, regulatory agencies worldwide restricted the use of the selective serotonin reuptake inhibitors (SSRIs) and other newer ATDs by children and adolescents due to their association with an increased risk of suicidal ideation and behaviour. The extent of use of these drugs by young people in UK general practice both before and after the restrictions was unknown. It was unclear when young people discontinued treatment for depression and whether this depended on the class of ATD prescribed. The impact of the restrictions on the clinical practices of specialist clinicians was also unknown. This thesis aimed to: 1) evaluate literature data on suicidality risk and newer ATDs; 2) investigate psychotropic drug prescribing trends, focusing on ATD use in general practice before and after the regulatory changes, and investigate treatment cessation for depression; 3) assess specialists' practices and opinions on the regulatory changes. Systematic literature review, pharmacoepidemiological techniques using large clinical databases (IMS Prescribing Insights, the General Practice Research Database, and IMS Disease Analyzer-Mediplus), and survey methods were employed. Global use of psychotropic drugs by young people increased between 2000 and 2002; prescription volume rose by 68% in the UK. Between 1992 and 2001, ATD prescribing to children and adolescents (≤18 years) increased by 70%, with SSRIs gaining popularity compared with tricyclic ATDs. However, between 2002 and 2004, the use of the restricted drugs declined by a third. More than half of depressed patients treated with ATDs discontinue or switch treatment within two months. In response to the regulatory changes specialist clinicians have restricted their use of ATDs despite some disagreeing with them. Resources for psychological therapies such as cognitive-behavioural therapy are limited.
4 citations
••
TL;DR: The clinician should consider the likelihood of adverse drug interactions to be a significant concern as the age of the patient and the number of concurrently administered medications increase.
4 citations
••
01 Jan 1979
TL;DR: In this paper, the acute efficacy of single oral dosages of 20 psychotropic drugs, 5 neuroleptics, 5 anxiolytics, 5 antidepressants and 5 psychostimulants plus 5 placebos has been tested in 5 basic studies simultaneously designed and performed and involving 75 healthy male volunteers.
Abstract: The acute efficacy of single oral dosages of 20 psychotropic drugs, 5 neuroleptics, 5 anxiolytics, 5 antidepressants and 5 psychostimulants plus 5 placebos has been tested in 5 basic studies simultaneously designed and performed and involving 75 healthy male volunteers. Each study was done in a Latin square double-blind design with 15 subjects, each receiving one placebo and one compound of each of the four clinical therapeutic psychotropic drug classes. Three 5-minute EEG recordings (pre, 1 hr. and 3 hr. post drug intake) are taken to represent the drug effects. The differences in drug efficacy were tested by multivariate analysis of variance using 3 × 7 power spectrum estimates selected from these 3 EEG recordings. 14 of the 20 substances could be distinguished from placebo at a 5%, 16 at a 10% level. In order to demonstrate the results visually, examples of the mean relative power estimates as well as the standard q-score profiles of the 7 variables at three times are given. All 7 variables selected contribute to the differences between the drugs. However, some variables seem to be more specific for a defined drug class than others:υ = 5.5 – 8.5 Hz for the neuroleptics, β1F = 12.0 – 18.0 Hz for the anxiolytics, α1F = 8.5 – 10.5 Hz for the psychostimulants and a combination of δF = 1.5 – 3.5 Hz, lF and α1F for the antidepressants.
4 citations